AbbVie (NYSE:ABBV) Issues FY 2026 Earnings Guidance

Key Points

• AbbVie issued FY 2026 EPS guidance of 13.960–14.160, below the consensus of 14.560, and updated Q1 2026 EPS guidance to 2.560–2.600.
• Analysts remain mixed but overall positive: MarketBeat shows a consensus rating of “Moderate Buy” with a consensus price target of $252.65 (individual targets range roughly $230–$299).
• AbbVie declared a quarterly dividend of $1.73 (annualized $6.92, ~3.3% yield) and is pursuing a lawsuit to narrow eligibility for a federal drug‑discount program—moves that could help protect revenue amid pricing pressure.

AbbVie (NYSE:ABBV - Get Free Report) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 13.960-14.160 for the period, compared to the consensus estimate of 14.560. The company issued revenue guidance of -. AbbVie also updated its Q1 2026 guidance to 2.560-2.600 EPS.

Analysts Set New Price Targets

A number of research firms have weighed in on ABBV. Royal Bank Of Canada began coverage on shares of AbbVie in a research report on Tuesday, February 24th. They issued an "outperform" rating and a $260.00 price target for the company. Berenberg Bank set a $275.00 price target on shares of AbbVie in a research report on Tuesday, January 20th. Piper Sandler upped their price target on shares of AbbVie from $289.00 to $299.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 18th. Weiss Ratings reiterated a "hold (c)" rating on shares of AbbVie in a research report on Wednesday, January 21st. Finally, Citigroup dropped their price target on shares of AbbVie from $235.00 to $230.00 and set a "neutral" rating for the company in a research report on Tuesday, January 27th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, AbbVie has a consensus rating of "Moderate Buy" and a consensus price target of $252.65.

AbbVie Price Performance

Shares of ABBV stock traded up $0.61 during mid-day trading on Thursday, hitting $212.20. The company had a trading volume of 992,419 shares, compared to its average volume of 7,181,494. AbbVie has a 52-week low of $164.96 and a 52-week high of $244.81. The stock's 50 day moving average price is $220.80 and its 200-day moving average price is $224.19. The company has a market capitalization of $375.21 billion, a P/E ratio of 90.05, a P/E/G ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. AbbVie's revenue was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts expect that AbbVie will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. AbbVie's dividend payout ratio is presently 293.22%.

Insiders Place Their Bets

In related news, EVP Perry C. Siatis sold 22,381 shares of the company's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company's stock, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the company's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The SEC filing for this sale provides additional information. 0.25% of the stock is owned by corporate insiders.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie sued the U.S. government seeking to narrow which patients qualify for a federal drug‑discount program — a move aimed at limiting mandatory discounts and protecting revenue/margins if the court sides with AbbVie. This is the biggest near‑term corporate action likely viewed favorably by investors concerned about pricing erosion. AbbVie files lawsuit to address 'outdated' drug discount eligibility program
• Positive Sentiment: New dermatology data presented for Skyrizi and Rinvoq (long‑term outcomes, safety and new indications data) could support continued sales momentum and broaden labels — reinforcing the company’s post‑Humira growth story that underpins guidance and cash generation. Can AbbVie’s (ABBV) New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story?
• Positive Sentiment: Dividend and cash‑flow narrative remains a tailwind: coverage highlights AbbVie’s high free cash flow, multi‑decade dividend streak and recent dividend raise — attractive to income investors and supportive of the stock’s defensive appeal. 3 Dividend Aristocrats Whose Yields Can Help Combat Inflation
• Neutral Sentiment: BOTOX® Cosmetic community program and consumer/brand initiatives continue (PR), helpful for aesthetics franchise branding but unlikely to move near‑term fundamentals materially. BOTOX® Cosmetic Empowers Women Entrepreneurs
• Neutral Sentiment: Cantor Fitzgerald trimmed its price target modestly (from $250 to $240) but kept an overweight rating — suggests confidence in upside over time even as near‑term expectations are fine‑tuned. Benzinga note on Cantor Fitzgerald price target change
• Negative Sentiment: J&J’s Tremfya reclaimed the top spot in TV drug ad spending from AbbVie — fewer or lower consumer ad dollars for AbbVie could signal reduced promotional support for its brands or a strategic pullback, a potential headwind to near‑term demand growth. J&J's Tremfya retakes TV drug ad spending crown from AbbVie
• Negative Sentiment: Participation in discount channels (e.g., Humira listed on TrumpRx at a steep discount) and political/program risks keep revenue exposure to pricing pressure top of mind for investors; the lawsuit seeks relief but regulatory/legal outcomes are uncertain. AbbVie Puts Humira on TrumpRx at Steep Discount
• Negative Sentiment: Analyst debate on valuation vs. pipeline growth persists — some coverage flags valuation doubts despite pipeline and operating leverage, which can cap near‑term upside until clarity on sustained product growth arrives. Why The AbbVie (ABBV) Story Is Shifting As Immunology Hopes Meet Valuation Doubts

Institutional Investors Weigh In On AbbVie

Hedge funds and other institutional investors have recently made changes to their positions in the company. Litman Gregory Wealth Management LLC bought a new stake in shares of AbbVie during the 4th quarter worth approximately $28,000. Imprint Wealth LLC boosted its holdings in AbbVie by 56.3% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock valued at $29,000 after acquiring an additional 45 shares during the period. IFC & Insurance Marketing Inc. purchased a new position in AbbVie during the 4th quarter valued at $31,000. Quarry LP purchased a new position in AbbVie during the 3rd quarter valued at $41,000. Finally, Jessup Wealth Management Inc purchased a new position in AbbVie during the 4th quarter valued at $42,000. Hedge funds and other institutional investors own 70.23% of the company's stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.